𝕏
Latest
Deals

Evommune Inks Up to $1.1bn Deal for Hinova Autoimmune Drug

Evommune (EVMN) has licensed rights to an experimental autoimmune disease treatment from China’s Hinova Pharmaceuticals (688302.SS) in a deal worth up to about $1.1bn in milestone payments.

Under the agreement, the California-based drug developer gains rights outside Greater China to develop, manufacture and commercialize EVO570, an oral drug designed to treat autoimmune diseases by targeting VAV1, a protein involved in activating immune cells.

Evommune will pay Hinova $30mn upfront, comprising $20mn in cash and $10mn in pre-funded warrants to purchase Evommune stock. Hinova is also eligible for up to about $1.1bn in development, regulatory and commercial milestone payments, as well as tiered royalties on future sales.

The deal expands Evommune’s pipeline of treatments for chronic inflammatory diseases and offers a potential entry into an immunology research area focused on VAV1, an emerging target for autoimmune conditions. The company plans to start a mid-stage study of the drug in rheumatoid arthritis in 2027.

Chengdu-based Hinova develops treatments for cancer, autoimmune and metabolic diseases, and already markets a prostate cancer therapy in China.

Related coverage

All news →